Scarica l'app Stockscreener
351.04
3.40%
11.93
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALNY Giù?
Forum
Previsione
Precedente Chiudi:
$339.11
Aprire:
$338.49
Volume 24 ore:
1.64M
Relative Volume:
1.18
Capitalizzazione di mercato:
$46.35B
Reddito:
$3.21B
Utile/perdita netta:
$43.57M
Rapporto P/E:
1,459.63
EPS:
0.2405
Flusso di cassa netto:
$221.36M
1 W Prestazione:
-1.16%
1M Prestazione:
-12.38%
6M Prestazione:
-12.74%
1 anno Prestazione:
+27.71%
Intervallo 1D:
$337.59
$352.82
Intervallo di 1 settimana:
$333.00
$356.84
Portata 52W:
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
Nome
Alnylam Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 551-8200
Indirizzo
675 WEST KENDALL STREET, CAMBRIDGE, MA
Confronta ALNY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
350.85 | 44.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.42 | 119.76B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
759.60 | 79.35B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
849.88 | 51.71B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
346.20 | 38.18B | 4.98B | 69.60M | 525.67M | 0.5198 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-07 | Ripresa | Oppenheimer | Outperform |
| 2025-08-04 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-08-04 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-12 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-08-16 | Aggiornamento | Goldman | Neutral → Buy |
| 2024-02-16 | Downgrade | Goldman | Buy → Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Equal Weight |
| 2023-10-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-09-29 | Iniziato | Raymond James | Outperform |
| 2023-05-05 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | Iniziato | SMBC Nikko | Neutral |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Buy |
| 2022-09-09 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-27 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-06-07 | Iniziato | William Blair | Outperform |
| 2022-04-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | Iniziato | Citigroup | Buy |
| 2022-02-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-01-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-11-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-10-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-08-04 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-02-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-02-12 | Reiterato | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | Ripresa | Berenberg | Hold |
| 2020-09-08 | Iniziato | Citigroup | Buy |
| 2020-08-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-04-24 | Ripresa | Evercore ISI | Outperform |
| 2020-03-19 | Iniziato | Berenberg | Buy |
| 2019-12-19 | Reiterato | Chardan Capital Markets | Buy |
| 2019-11-20 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-05-23 | Ripresa | Goldman | Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-06 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-03-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | Iniziato | UBS | Neutral |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-08-13 | Reiterato | Stifel | Buy |
| 2018-08-07 | Aggiornamento | Stifel | Hold → Buy |
| 2018-05-04 | Reiterato | Stifel | Hold |
| 2018-03-28 | Iniziato | Evercore ISI | In-line |
Mostra tutto
Alnylam Pharmaceuticals Inc Borsa (ALNY) Ultime notizie
25,451 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Mediolanum International Funds Ltd - MarketBeat
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth - Insider Monkey
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness - Yahoo Finance
Alnylam Pharmaceuticals (ALNY) Receives Analyst Rating Update fr - GuruFocus
Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity? - simplywall.st
Morgan Stanley Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
ALNY: Morgan Stanley Adjusts Price Target Amidst Equal-Weight Ra - GuruFocus
H.C. Wainwright raises Alnylam Pharmaceuticals stock price target on TTR franchise potential - Investing.com Canada
Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $510.00 Price Target at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains Buy Rating on ALNY, Lowers Price T - GuruFocus
What analysts say about Alnylam Pharmaceuticals Inc. stockGold Moves & Safe Swing Trade Setups - Mfd.ru
Alnylam Pharmaceuticals Projects 2026 Revenue Around $5.3 Billion as It Focuses on a New Five-Year Strategy - Finviz
What Alnylam Pharmaceuticals (ALNY)'s Analyst Re-Rating on Amvuttra and Pipeline Prospects Means For Shareholders - simplywall.st
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results - Business Wire
Whale Trades: Should I hold or sell Alnylam Pharmaceuticals Inc nowWeekly Profit Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Barclays Initiates Coverage on Alnylam Pharmaceuticals (ALNY) wi - GuruFocus
Street Watch: Does Alnylam Pharmaceuticals Inc have a sustainable dividendQuarterly Investment Review & Stock Portfolio Risk Control - baoquankhu1.vn
J. Safra Sarasin Holding AG Has $4.34 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Earns Overweight Rating from Analysts at Barclays - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile - Chartmill
Federated Hermes Inc. Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook - Intellectia AI
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? - AOL.com
Wells Fargo Raises Alnylam (ALNY) Revenue Estimates for Amvuttra Despite Projected Margin Compression - Finviz
Aug Shorts: Is Alnylam Pharmaceuticals Inc impacted by rising rates2025 Earnings Impact & Safe Investment Capital Preservation Plans - baoquankhu1.vn
EFG Asset Management North America Corp. Trims Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What are analysts’ price targets for Alnylam Pharmaceuticals Inc.Weekly Gains Summary & Stepwise Entry and Exit Trade Signals - mfd.ru
The Five Minute Read - Lowell Sun
Mitsubishi UFJ Trust & Banking Corp Sells 8,273 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
A Look At Alnylam Pharmaceuticals (ALNY) Valuation As 2026 Revenue Guidance Signals Strong Growth Potential - simplywall.st
Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Jennison Associates LLC Has $139.02 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Baillie Gifford & Co. Cuts Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Should Alnylam’s Aggressive 2026 Revenue Guidance Reframe the Risk‑Reward for Alnylam Pharmaceuticals (ALNY) Investors? - simplywall.st
31,152 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Bought by Rakuten Investment Management Inc. - MarketBeat
Nanomedicine Market Reached USD 169.51 Billion in 2024, to Reach - openPR.com
Alnylam Pharmaceuticals CMO sells shares worth $14.99 million - MSN
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica - GlobeNewswire Inc.
Technical Reactions to ALNY Trends in Macro Strategies - Stock Traders Daily
RBC Capital Maintains Rating but Lowers Alnylam Pharmaceuticals (ALNY) Price Target | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $376.00 Price Target at Wells Fargo & Company - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Lowered to $465.00 at Royal Bank Of Canada - MarketBeat
356,529 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Massachusetts Financial Services Co. MA - MarketBeat
Allstate Corp Acquires Shares of 4,571 Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Price Action: What analysts say about Alnylam Pharmaceuticals Inc stockWeekly Investment Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
4 Next-Gen Candidates That Could Form the Future of Alzheimer’s Treatment - BioSpace
Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Significant Growth in Short Interest - MarketBeat
Aug Volume: How does Alnylam Pharmaceuticals Inc perform in inflationary periodsJuly 2025 Opening Moves & Stock Portfolio Risk Management - baoquankhu1.vn
Alnylam Pharmaceuticals Inc Azioni (ALNY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Alnylam Pharmaceuticals Inc Azioni (ALNY) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Jan 12 '26 |
Sale |
362.86 |
9,577 |
3,475,157 |
78,411 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Jan 12 '26 |
Sale |
362.87 |
2,780 |
1,008,766 |
57,465 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Jan 12 '26 |
Sale |
362.87 |
1,510 |
547,927 |
29,728 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Jan 13 '26 |
Sale |
370.33 |
2,290 |
848,065 |
21,264 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Jan 12 '26 |
Sale |
362.87 |
1,510 |
547,927 |
23,554 |
1.67%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):